Navigation Links
K-V Pharmaceutical Company Receives Notification From New York Stock Exchange of Compliance With Quantitative Continued Listing Standards
Date:9/2/2010

ST. LOUIS, Sept. 2 /PRNewswire/ -- K-V Pharmaceutical Company (NYSE:  KVa/KVb) announced today that it has received notification from the New York Stock Exchange ("NYSE") stating that the Company has reestablished compliance with the NYSE's minimum share price requirements for continued listing on an accelerated basis.

The NYSE's notification confirmed that the average price of the Company's Class A Common Stock for the 30-trading days ended August 31, 2010, as well as the share price on August 31, 2010, exceeded the NYSE's minimum requirement of $1.00.

Greg Divis, Interim President and Chief Executive Officer of K-V, stated, "We are pleased that the Company's stock price has returned to compliance with the NYSE minimum for continued listing.   While we still face many challenges, we are working hard to continue moving the Company forward."

The Company noted that it will remain under review by the NYSE because of the delay in filing its Form 10-K for the fiscal year ended March 31, 2010. The Company currently is working with its independent registered accountants, BDO USA, LLP, to file the report as soon as possible and to become current with all of its periodic SEC reporting.  

About K-V Pharmaceutical Company

K-V Pharmaceutical Company is a fully-integrated specialty pharmaceutical company that develops, manufactures, markets and acquires technology-distinguished branded prescription products.  The Company markets its technology-distinguished products through Ther-Rx Corporation, its branded drug subsidiary.

For further information about K-V Pharmaceutical Company, please visit the Company's website at www.kvpharmaceutical.com.

Cautionary Note Regarding Forward-looking Statements

This press release contains various forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1
'/>"/>

SOURCE K-V Pharmaceutical Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... 6, 2015 According to ... Isolation Market by Technology (Precipitation, Dialysis, Electrophoresis, Western ... (Instruments, Kits, Reagents, Resins) by Application & End ... MarketsandMarkets,  the global Protein Purification and Isolation Market ... and is expected to reach $ 6,370 Million ...
(Date:5/6/2015)... May 6, 2015   Symbiomix Therapeutics today ... and final tranche of a $41 million Series A ... 2 trial testing a single oral dose of SYM-1219 ... discussions with the U.S. Food and Drug Administration (FDA) ... planning to submit the Phase 2 trial as one ...
(Date:5/5/2015)... BARCELONA, Spain , May 6, 2015 ... and aspires to lead the European market in the ... Through this alliance ECUPHAR acquires all the assets ... the new organization in the coming weeks. Being both ... not been disclosed.      (Photo: http://photos.prnewswire.com/prnh/20150506/743274 ...
Breaking Medicine Technology:Protein Purification and Isolation Market Worth $6,370 Million by 2020 2Protein Purification and Isolation Market Worth $6,370 Million by 2020 3Protein Purification and Isolation Market Worth $6,370 Million by 2020 4Symbiomix Therapeutics Announces Closing of $41M Financing and Positive Results from a Pivotal Phase 2 Trial of SYM-1219 for the Treatment of Bacterial Vaginosis 2Symbiomix Therapeutics Announces Closing of $41M Financing and Positive Results from a Pivotal Phase 2 Trial of SYM-1219 for the Treatment of Bacterial Vaginosis 3Symbiomix Therapeutics Announces Closing of $41M Financing and Positive Results from a Pivotal Phase 2 Trial of SYM-1219 for the Treatment of Bacterial Vaginosis 4Symbiomix Therapeutics Announces Closing of $41M Financing and Positive Results from a Pivotal Phase 2 Trial of SYM-1219 for the Treatment of Bacterial Vaginosis 5ECUPHAR Enters the Spanish and Southern European Markets Through ESTEVE 2
... International (OTC Bulletin Board: SNDZ ) said ... will be introduced in October to eye doctors and ... been planned by its Indian distributors, New Amsterdam Marketing ...  The company,s Pneumatic Trabeculoplasty (PNT), treatment is a cost-effective, ...
... one of the world,s leading research and advisory ... oncologists will be the most aggressive in adopting ... lower clinical trial requirements. According to Biosimilars ... on Biosimilar G-CSFs and MAbs in Oncology , ...
Cached Medicine Technology:Sunridge to Introduce Their PNT Treatment for Glaucoma to Medical Personnel in India 2Oncologists Will Be More Aggressive In Adopting Biosimilars Compared With Other Specialties 2
(Date:5/6/2015)... 06, 2015 Established by the Arthritis ... the estimated 46 million Americans who suffer from arthritis. ... medications to alleviate their symptoms. Medicationdiscountcard.com is proud to ... patients money on the costs of these necessary prescriptions. ... to treat the pain and inflammation in the joints ...
(Date:5/6/2015)... 06, 2015 The Jefferson Awards ... to activating and celebrating public service, announced today ... Health, as an Outstanding Employee Volunteer Organization. Champions ... Awards Foundation, are dedicated to building a culture ... decade, Highmark Health has recognized employees who volunteer ...
(Date:5/6/2015)... Stout Industries is owned and operated by ... Texas fire departments. Stout Industries recently developed Fire-ground Injury ... to these fire safety devices. The departure lights are ... turned on. They light the area within 50 feet of ... the roof, preventing leg and ankle injuries. In 2013 ...
(Date:5/6/2015)... NH (PRWEB) May 06, 2015 Launch Corporation, ... has opened its new Nashua location at 17 Tanguay Avenue. ... will be the duo’s second Launch location in New England. ... their new team,” said Rob Arnold, founder, co-owner and CEO ... location and we look forward to seeing them continue to ...
(Date:5/6/2015)... (PRWEB) May 06, 2015 The SGNY ... New York City, announced today that it was named ... for a presentation video produced on behalf of Intarcia ... the category of motion graphics. , The competition sponsored ... received over 6000 entries from 22 countries. The ...
Breaking Medicine News(10 mins):Health News:Medicationdiscountcard.com Provides Access to Drug Coupons for Arthritis Awareness Month 2Health News:Medicationdiscountcard.com Provides Access to Drug Coupons for Arthritis Awareness Month 3Health News:The Jefferson Awards Foundation Honors Highmark Health 2Health News:The Jefferson Awards Foundation Honors Highmark Health 3Health News:The Jefferson Awards Foundation Honors Highmark Health 4Health News:Kickstarter for FIRE Lights, the New Fire Safety Devices 2Health News:Jump Up and Celebrate: Launch Trampoline Park Opens in Nashua, NH 2Health News:The SGNY Group Wins Platinum Hermes Creative Award 2
... 23 Niutang Chemical, a leading,global manufacturer of ... Alan Turner to lead its new office in ... Ltd., Mr. Turner will,spearhead all of Nuitang,s sales ... acid. He will particularly focus on the company,s,fast-growing ...
... WellPoint, Inc. (NYSE:,WLP) today announced the appointment ... segment, effective July 8, 2008., In his ... WellPoint,s,Individual Business segment, which currently serves more than ... add the quality of experience and,strategic expertise that ...
... individuals had more advanced disease and were less likely ... News) -- Low socioeconomic status increases a cancer patient,s ... on almost 14,000 breast, prostate and colorectal patients in ... patients with low socioeconomic status had more advanced cancers ...
... discovery holds promise as a treatment target for this diverse ... Cancerous myeloma cells are so "addicted" to a gene known ... has revealed. , Reducing the activity of the gene by ... compromising other healthy activities, said scientists reporting in the current ...
... AFAM ) announced today that it is scheduled to ... of market on June 27,according to a preliminary list of ... B. Yarmuth, President and CEO of Almost Family, Inc., stated,"We ... end of June as,it will provide greater awareness and visibility ...
... Before Disaster ... Fans, Players and Coaches, CLEVELAND, June 23 The ... -- able to,detect hidden flaws or developed stress within Major ... -- will be introduced as,BatteryMate(TM) on June 27, 2008, at ...
Cached Medicine News:Health News:Niutang Recruits Seasoned Executive to Open U.K. Office 2Health News:WellPoint Appoints Raj G. Bal as President of Individual Business 2Health News:Poorer Patients Have Poorer Survival After Cancer Diagnosis 2Health News:One Gene May Be Key to Myeloma 2Health News:One Gene May Be Key to Myeloma 3Health News:Almost Family, Inc. Set to Join to Russell 2000(R) Index 2Health News:Bat Scan to the Rescue: New Clubhouse CT Scanner Helps Eliminate Exploding Bats 2Health News:Bat Scan to the Rescue: New Clubhouse CT Scanner Helps Eliminate Exploding Bats 3
...
...
... FLEXILOG antimony pH catheters are designed for ... ,All catheters are number marked at 5cm ... ,More than sixteen individual models are available spanning ... single-use or multi-use models with one or two ...
... are designed using established technology providing ... benefits:, ,Working with pH catheters ... the multi-use catheter is used the ... to the skin.,NOTE: ,Medtronic pH measurement ...
Medicine Products: